Clearmind Medicine (Clearmind Medicine) FCF Margin % : 0.00% (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Clearmind Medicine FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Clearmind Medicine's Free Cash Flow for the three months ended in Jan. 2024 was $-1.46 Mil. Clearmind Medicine's Revenue for the three months ended in Jan. 2024 was $0.00 Mil. Therefore, Clearmind Medicine's FCF Margin % for the quarter that ended in Jan. 2024 was 0.00%.

As of today, Clearmind Medicine's current FCF Yield % is -75.33%.

The historical rank and industry rank for Clearmind Medicine's FCF Margin % or its related term are showing as below:

CMND's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.09
* Ranked among companies with meaningful FCF Margin % only.

Clearmind Medicine FCF Margin % Historical Data

The historical data trend for Clearmind Medicine's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearmind Medicine FCF Margin % Chart

Clearmind Medicine Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

FCF Margin %

Get a 7-Day Free Trial

Clearmind Medicine Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Clearmind Medicine's FCF Margin %

For the Biotechnology subindustry, Clearmind Medicine's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clearmind Medicine's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clearmind Medicine's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Clearmind Medicine's FCF Margin % falls into.

Clearmind Medicine FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Clearmind Medicine's FCF Margin for the fiscal year that ended in Oct. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Oct. 2023 )	/	Revenue (A: Oct. 2023 )
	=	-4.557	/	0
	=	%

Clearmind Medicine's FCF Margin for the quarter that ended in Jan. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jan. 2024 )	/	Revenue (Q: Jan. 2024 )
	=	-1.462	/	0
	=	%

Clearmind Medicine FCF Margin % Related Terms

Thank you for viewing the detailed overview of Clearmind Medicine's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearmind Medicine (Clearmind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearmind Medicine Inc (NAS:CMND) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

CWY0:Germany CWY0:Germany CMND:Canada

Address

101-1220 West 6th Avenue, Vancouver, BC, CAN, V6H 1A5

Website

https://www.clearmindmedicine.com

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.